T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Canadian Natural Resources
CNQ
|
+$759M |
| 3 |
Becton Dickinson
BDX
|
+$735M |
| 4 |
Ashland
ASH
|
+$669M |
| 5 |
Keysight
KEYS
|
+$573M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$1.73B |
| 2 |
Ecolab
ECL
|
+$1.17B |
| 3 |
Crown Castle
CCI
|
+$906M |
| 4 |
Phillips 66
PSX
|
+$775M |
| 5 |
Gilead Sciences
GILD
|
+$756M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.84% |
| 2 | Consumer Discretionary | 13.93% |
| 3 | Financials | 13.41% |
| 4 | Industrials | 12.4% |
| 5 | Technology | 9.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Clearwater Paper
CLW
$356M
| $183M | 0.04% |
2,675,451
-460,795
| -15% | -$30.7M |
|
452
Ally Financial
ALLY
$13.5B
| $183M | 0.04% |
7,734,180
+2,804,500
| +57% | +$63.4M |
|
|
WRI
453
DELISTED
Weingarten Realty Investors
WRI
| $183M | 0.04% |
5,228,792
-335,090
| -6% | -$11.7M |
|
|
KATE
454
DELISTED
Kate Spade & Company
KATE
| $182M | 0.04% |
5,678,069
-2,593,917
| -31% | -$74M |
|
455
Franklin Electric
FELE
$4.75B
| $181M | 0.04% |
4,819,915
+492,180
| +11% | +$18.2M |
|
|
TW
456
DELISTED
TOWERS WATSON & CO COM STK CL A (DE)
TW
| $181M | 0.04% |
1,595,052
+675,718
| +74% | +$74.5M |
|
457
Adtran
ADTN
$665M
| $180M | 0.04% |
8,269,583
+112,840
| +1% | +$2.31M |
|
458
EastGroup Properties
EGP
$10.9B
| $180M | 0.04% |
2,839,530
+12,720
| +0.4% | +$829K |
|
|
SEM
459
DELISTED
Select Medical
SEM
| $179M | 0.04% |
23,126,979
+3,473,893
| +18% | +$25.3M |
|
460
Glacier Bancorp
GBCI
$6.4B
| $179M | 0.04% |
6,433,026
-17,100
| -0.3% | -$464K |
|
461
Capitol Federal Financial
CFFN
$1.1B
| $179M | 0.04% |
13,972,561
-82,900
| -0.6% | -$1.04M |
|
462
RBC Bearings
RBC
$17.6B
| $178M | 0.04% |
2,763,715
-247,239
| -8% | -$15M |
|
463
Valmont Industries
VMI
$9.52B
| $178M | 0.04% |
1,399,024
-277,558
| -17% | -$37.1M |
|
464
Mercado Libre
MELI
$92.7B
| $177M | 0.04% |
1,382,892
-222,366
| -14% | -$28.1M |
|
465
Host Hotels & Resorts
HST
$15.6B
| $176M | 0.04% |
7,383,615
-118,841
| -2% | -$2.71M |
|
466
BioMarin Pharmaceuticals
BMRN
$13.6B
| $175M | 0.04% |
1,938,782
-98,611
| -5% | -$8.2M |
|
467
Acadia Healthcare
ACHC
$2.95B
| $174M | 0.04% |
2,849,243
+14,573
| +0.5% | +$848K |
|
|
QUOT
468
DELISTED
Quotient Technology Inc
QUOT
| $173M | 0.04% |
9,746,268
+471,951
| +5% | +$7.02M |
|
469
Colgate-Palmolive
CL
$73.6B
| $173M | 0.04% |
2,493,334
-59,824
| -2% | -$4.04M |
|
470
Semtech
SMTC
$13B
| $171M | 0.04% |
6,198,700
-159,510
| -3% | -$4.07M |
|
471
Centene
CNC
$33.1B
| $170M | 0.04% |
6,558,724
+12,084
| +0.2% | +$282K |
|
472
Camden Property Trust
CPT
$10.9B
| $170M | 0.04% |
2,303,935
-9,130
| -0.4% | -$676K |
|
|
USG
473
DELISTED
Usg
USG
| $170M | 0.04% |
6,058,150
+5,200
| +0.1% | +$143K |
|
474
Expeditors International
EXPD
$24B
| $169M | 0.04% |
3,788,210
+124,285
| +3% | +$5.34M |
|
|
BERY
475
DELISTED
Berry Global Group, Inc.
BERY
| $169M | 0.04% |
5,824,099
+109,019
| +2% | +$2.73M |
|
Similar funds
T. Rowe Price Associates's Q4 2014 Portfolio in Review
As of Q4 2014, T. Rowe Price Associates held 2,627 positions worth $471B, up 2.8% from $458B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q4 2014 filing shows 87 new, 929 increased, 999 reduced and 89 closed positions. Its largest new stake was Keysight: 17,553,953 shares worth $593M. The largest sale was RTX Corp, an estimated $1.73B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q4 2014 buy was Keysight: 17,553,953 shares worth $593M.
- T. Rowe Price Associates added most to Allergan plc in Q4 2014, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2014 reduction was RTX Corp, cutting an estimated $1.73B.
- T. Rowe Price Associates fully exited ATHLON ENERGY INC COM in Q4 2014, selling an estimated $499M.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $471B portfolio in Q4 2014.
- T. Rowe Price Associates opened 87 new positions and closed 89 in Q4 2014.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $471B.
Based on T. Rowe Price Associates's 13F filing for Q4 2014, filed 13 Feb 2015.